These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32538547)

  • 1. Alpha-Synuclein Dopaminylation Presented in Plasma of Both Healthy Subjects and Parkinson's Disease Patients.
    Zhao H; Huang S; Palanisamy S; Wang C; Rainer G; Zhang X
    Proteomics Clin Appl; 2020 Sep; 14(5):e1900117. PubMed ID: 32538547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease.
    Sivakumar P; Nagashanmugam KB; Priyatharshni S; Lavanya R; Prabhu N; Ponnusamy S
    Neurochem Int; 2023 Jan; 162():105461. PubMed ID: 36460239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease.
    Kang SS; Zhang Z; Liu X; Manfredsson FP; Benskey MJ; Cao X; Xu J; Sun YE; Ye K
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10773-10778. PubMed ID: 28923922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.
    Foulds PG; Mitchell JD; Parker A; Turner R; Green G; Diggle P; Hasegawa M; Taylor M; Mann D; Allsop D
    FASEB J; 2011 Dec; 25(12):4127-37. PubMed ID: 21865317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
    Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
    Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression.
    Niu M; Li Y; Li G; Zhou L; Luo N; Yao M; Kang W; Liu J
    Eur J Neurol; 2020 Jun; 27(6):967-974. PubMed ID: 32150777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
    Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
    Mov Disord; 2010 Mar; 25(4):489-93. PubMed ID: 20063406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
    Wang X; Yu S; Li F; Feng T
    Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
    Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
    Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients.
    Nam D; Lee JY; Lee M; Kim J; Seol W; Son I; Ho DH
    J Parkinsons Dis; 2020; 10(3):981-991. PubMed ID: 32444560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein in blood cells differentiates Parkinson's disease from healthy controls.
    Abd Elhadi S; Grigoletto J; Poli M; Arosio P; Arkadir D; Sharon R
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2426-2436. PubMed ID: 31742923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α-Synuclein in Parkinson's Disease.
    Wang L; Wang G; Duan Y; Wang F; Lin S; Zhang F; Li H; Li A; Li H
    Neurodegener Dis; 2019; 19(5-6):204-210. PubMed ID: 32485710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson's Disease.
    Folke J; Rydbirk R; Løkkegaard A; Salvesen L; Hejl AM; Starhof C; Bech S; Winge K; Christensen S; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
    Front Immunol; 2019; 10():2253. PubMed ID: 31616427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrated alpha-synuclein in minor salivary gland biopsies in Parkinson's disease.
    Ma LY; Gao LY; Li X; Ma HZ; Feng T
    Neurosci Lett; 2019 Jun; 704():45-49. PubMed ID: 30946930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
    El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
    FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.